Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMHCI9S)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Cordran; Drenison; Drocort; Floudroxycortide; Fludrossicortide; Fludroxicortida; Fludroxicortidum; Fludroxycortide; Fludroxycortidum; Fluorandrenolone; Fluradrenolide; Flurandrenolone; Haelan; Sermaka; CORDRAN SP; Fludrossicortide [DCIT]; Fluorandrenolone acetonide; Flurandrenolide [USAN]; Flurandrenolone acetonide; L 33379; Alondra-F; CORDRAN (TN); Cordran tape (TN); Fludroxicortida [INN-Spanish]; Fludroxycortidum [INN-Latin]; Flurandrenolide (USP); Haldrone-F; Fludroxycortide (JAN/INN); Acetonide of 6alpha-fluoro-16alpha-hydroxyhydrocortisone; Pregn-4-ene-3,20-dione, 6alpha-fluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; Pregn-4-ene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic 16,17-acetal with acetone; 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxyprogesterone cyclic 16,17-acetal with acetone; 6alpha-Fluoro-16alpha-hydroxyhydrocortisone 16,17-acetonide
| |||||
| Therapeutic Class | Antiinflammatory Agents | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||
|
|||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Breast epithelium
Normal
Cervix
Cervical adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Normal (Transformed)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Pancreas
Pancreatic carcinoma
Peripheral blood
Acute monocytic leukemia
T-cell acute lymphoblastic leukemia
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
